MindRank Initiates Phase III ‘MOBILE’ Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI


HANGZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) — MindRank, a clinical-stage artificial intelligence (AI)-empowered drug discovery company, today announced the initiation of “MOBILE,” a pivotal Phase III clinical trial evaluating its lead candidate, MDR-001. MDR-001 is a proprietary, orally available GLP-1 receptor agonist (GLP-1RA) for chronic weight management, developed using the company’s Molecule Pro™ AI platform.



Source link

  • Related Posts

    AI Juggernaut Rumbles on Even as Markets Whipsaw

    (Bloomberg) — The artificial intelligence credit juggernaut keeps pushing forward as the relentless demand for exposure to the industry trumps fears that the conflict in the Middle East is causing…

    Manhattan DA’s office to investigate Swalwell sexual assault allegation

    The Manhattan District Attorney’s Office in New York has launched an investigation into a sexual assault allegation against Rep. Eric Swalwell, D-Calif., NBC News confirmed Saturday. Subscribe to read this…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    A basic TV sound booster

    A basic TV sound booster

    Grand National 2026: I Am Maximus wins again at Aintree for trainer Willie Mullins, repeating Red Rum feat

    Grand National 2026: I Am Maximus wins again at Aintree for trainer Willie Mullins, repeating Red Rum feat

    Hundreds of New Brunswick local government campaigns get underway

    Hundreds of New Brunswick local government campaigns get underway

    Killing of Masood Masjoody Exposes Deep Rifts in Canada’s Iranian Diaspora

    Takeaways From the First Big Gathering of Potential 2028 Democratic Candidates

    AI Juggernaut Rumbles on Even as Markets Whipsaw